These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33388397)

  • 41. Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mortality and Major Bleeding in Acute Coronary Syndromes.
    Manzano-Fernández S; Sánchez-Martínez M; Flores-Blanco PJ; López-Cuenca Á; Gómez-Molina M; Pastor-Pérez FJ; Sánchez-Galian MJ; Cambronero-Sanchez F; Guerrero Pérez E; García-Narbón A; de Las Heras-Gómez I; Valdés M
    Am J Cardiol; 2016 Apr; 117(7):1047-54. PubMed ID: 26857164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.
    Raposeiras-Roubín S; Caneiro Queija B; D'Ascenzo F; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Varbella F; Tomassini F; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Baz-Alonso JA; Calvo-Iglesias F; Valdés M; Cequier Á; Gaita F; Alexopoulos D; Íñiguez-Romo A; Abu-Assi E
    Rev Esp Cardiol (Engl Ed); 2019 Mar; 72(3):215-223. PubMed ID: 30029980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.
    Palmerini T; Bruno AG; Gilard M; Morice MC; Valgimigli M; Montalescot G; Collet JP; Della Riva D; Bacchi-Reggiani ML; Steg PG; Diallo A; Vicaut E; Helft G; Nakamura M; Généreux P; Vahl TP; Stone GW
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007541. PubMed ID: 30871353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients.
    Abu-Assi E; Raposeiras-Roubin S; Cobas-Paz R; Caneiro-Queija B; Martínez-Reglero C; Rodríguez-Rodríguez JM; Baz A; Íñiguez-Romo A
    EuroIntervention; 2018 Mar; 13(16):1914-1922. PubMed ID: 29131804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
    Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
    Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines.
    Ueki Y; Karagiannis A; Zanchin C; Zanchin T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Otsuka T; Hunziker L; Heg D; Moschovitis A; Seiler C; Billinger M; Pilgrim T; Valgimigli M; Windecker S; Räber L
    JACC Cardiovasc Interv; 2019 May; 12(9):820-830. PubMed ID: 30981574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy.
    Choi SY; Kim MH; Serebruany V
    TH Open; 2018 Oct; 2(4):e399-e406. PubMed ID: 31249967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline anemia in patients undergoing percutaneous coronary intervention after an acute coronary syndrome-A paradox of high bleeding risk, high ischemic risk, and complex coronary disease.
    Yazji K; Abdul F; Elangovan S; Ul Haq MZ; Ossei-Gerning N; Morris K; Anderson R; Kinnaird T
    J Interv Cardiol; 2017 Oct; 30(5):491-499. PubMed ID: 28707308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guideline-Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome.
    Hammer Y; Iakobishvili Z; Hasdai D; Goldenberg I; Shlomo N; Einhorn M; Bental T; Witberg G; Kornowski R; Eisen A
    J Am Heart Assoc; 2018 Sep; 7(18):e009885. PubMed ID: 30371188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.
    Orban M; Trenk D; Geisler T; Rieber J; Hadamitzky M; Gross L; Orban M; Kupka D; Baylacher M; Müller S; Huber K; Koltowski L; Huczek Z; Heyn J; Jacobshagen C; Aradi D; Massberg S; Sibbing D; Hein R;
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):372-381. PubMed ID: 31855244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Bavishi C; Trivedi V; Singh M; Katz E; Messerli FH; Bangalore S
    Am J Med; 2017 Nov; 130(11):1325.e1-1325.e12. PubMed ID: 28623176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-ST-elevation acute coronary syndromes in octogenarians: applicability of the GRACE and CRUSADE scores.
    Faustino A; Mota P; Silva J;
    Rev Port Cardiol; 2014 Oct; 33(10):617-27. PubMed ID: 25312887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization.
    Elbarasi E; Goodman SG; Yan RT; Welsh RC; Kornder J; Wong GC; Déry JP; Anderson F; Gore JM; Fox KA; Yan AT; ;
    Am Heart J; 2010 Jan; 159(1):40-6. PubMed ID: 20102865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.
    Nagashima Z; Tsukahara K; Uchida K; Hibi K; Karube N; Ebina T; Imoto K; Kimura K; Umemura S
    J Cardiol; 2017 Jan; 69(1):156-161. PubMed ID: 26987791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.